CSL Behring joins the ABPI

The ABPI is pleased to announce that CSL Behring has become a new full member from February 2022.

CSL Behring UK is a global leader in the plasma protein biotherapies industry. It researches, develops, manufactures and markets biotherapies which are used to treat serious and rare conditions. In the UK it specialises currently in haematology and immunology. 

CSL Behring combines research and development excellence with world-class patient care, and will add to the ABPI membership’s drive in making the UK the best place in the world to research, develop and use new medicines. The ABPI now has 65 full member companies, including the top 15 of the world’s biggest pharmaceutical companies.

Christian Wieszner, CSL Behring’s General Manager, UK and Ireland, said: “Our decision to become a full ABPI member underlines our commitment to developing and supplying innovative medicines that will improve the lives of people with rare diseases. We look forward to playing an active role across the ABPI’s work and in helping to shape the future of the pharmaceutical industry.”

Richard Torbett, ABPI’s Chief Executive said:

“We are delighted to have CSL Behring join us. Their wealth of experience in cutting-edge science, as well as a commitment to improving the lives of people with rare diseases around the world, mean they will be a valuable addition to ABPI’s membership.

“The ABPI now represents over 90 per cent of the UK’s branded medicines market, putting us in an even stronger place to deliver on our ambitions and make the UK the best place in the world to research, develop and use new medicines.”